genome-writing-inserts-human-x-linked-disease-dna-into-mice
Genome Writing Inserts Human X-Linked Disease DNA Into Mice

Genome Writing Inserts Human X-Linked Disease DNA Into Mice

By assembling and swapping in long stretches of engineered DNA with genome writing, researchers can reconstruct human disease-linked regions in another species—an approach that has now produced a mouse model of X-linked dystonia-parkinsonism (XDP), a rare neurodegenerative disorder that causes movement problems that worsen with age. The model compresses a disease course that can take decades in people into less than two months in mice, potentially accelerating studies of disease biology and treatments.

For the study, “Genome writing reveals SVA retrotransposon consequences in X-linked dystonia-parkinsonism,” published in Cell, an NYU Langone Health-led team rewrote part of the mouse Taf1 gene with a corresponding 78-kilobase segment of patient-derived human TAF1 DNA. That segment included a disease-causing SINE-VNTR-Alu (SVA) retrotransposon insertion. Because SVAs are found in humans but not mice, conventional mouse models cannot readily reproduce their effects.

In mouse embryonic stem cells, the researchers found that the intronic SVA—not the hybrid human-mouse gene structure itself—reduced TAF1 messenger RNA. Chromatin and transcriptome analyses indicated that the insertion is actively transcribed and acts as a barrier that may prematurely halt transcription, lowering TAF1 expression and triggering cell death. In mice, nervous system expression of the humanized TAF1 allele produced severe atrophy centered in the striatum, the brain region affected in people with XDP. Male mice died within two months, versus the roughly 30 years it can take for symptoms to emerge in humans.

The team also used CRISPR activation, or CRISPRa, to increase TAF1 expression in the engineered stem cells. Restoring expression rescued cell viability, offering proof of concept that boosting TAF1 transcription could be explored as a treatment strategy. “Our experiments establish a rationale for the future development of new therapeutic approaches for XDP patients,” said senior author Jef D. Boeke, PhD, director of NYU Langone’s Institute for Systems Genetics.

A companion Cell study, titled “Myelin pathology is a key feature of X-linked dystonia-parkinsonism,” using the same model further implicated oligodendrocytes—the cells that produce myelin around neuronal axons—rather than neurons alone in XDP. The researchers also detected myelin loss in banked human XDP brain tissue, a feature reportedly missed in earlier studies.

The work positions genome writing as a way to build models for diseases driven by large or human-specific DNA elements that are difficult to reproduce through conventional editing. Important questions remain, including what factors drive variable progression rates in XDP, whether raising TAF1 levels can safely produce durable benefits in animals, and how broadly the method can be applied to other rare diseases.